The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders

Maddison, P.; Titulaer, M.J.; Verschuuren, J.J.; Gozzard, P.; Lang, B.; Irani, S.R.; ... ; Chapman, C.J. (2019)

Article / Letter to editor

Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneoplastic disorders and controls.SOX2 antibodies were detectable in 61% of patients with LEMS-SCLC, and in other paraneoplastic disorders, such as opsoclonus-myoclonus and paraneoplastic cerebellar degeneration, only when there was an underlying SCLC.SOX2 antibodies are specific (> 90%) markers for SCLC, but are rarely found in patients with other tumours, whether neurological symptoms are present or not.

• SOX2
• Antibodies
• Paraneoplastic
• Lambert-Eaton myasthenic syndrome
• Small-cell lung cancer

• All authors: Maddison, P.; Titulaer, M.J.; Verschuuren, J.J.; Gozzard, P.; Lang, B.; Irani, S.R.; Sabater, L.; Graus, F.; Murray, A.; Chapman, C.J.
• Date: 2019-01-15
• Journal: Journal of Neuroimmunology
• Volume: 326
• Pages: 14 - 18
• DOI: doi:10.1016/j.jneuroim.2018.11.003